Myeloma 2016: Panel discussion on novel treatments
Keith Stewart et al.
What is the role of inotuzumab ozogamicin in ALL
The current status of CLL treatment and how clinical practice will change
Interim results of pegylated interferon alpha-2a for polycythemia vera and essential thrombocythemia
An overview of iwCLL 2017 meeting in New York by Prof. Michael Hallek